nPhase Raises $30M Series D

nPhase, based in Atlantic Beach, Florida, is a clinical research technology company providing an AI-native platform for pharmaceutical sponsors. The company announced it has secured $30 million in a Series D funding round, marking its first equity raise since 2017.

Investors

The funding round was led by Viking Global Investors, an investment firm managing over $54 billion in capital across public and private markets.

nPhase Use of Funds

nPhase plans to use the new capital to scale its enterprise clinical data business. Specifically, the funds will accelerate the expansion of its Statistical Computing Environment (SCE), Unified Data Management System (UDMS), and the development of new agentic AI capabilities designed to streamline the clinical data lifecycle.

About nPhase

Founded to modernize clinical research technology, nPhase provides a unified and governed foundation for clinical data management. Its flagship platform, nPhase.ai, connects the clinical data lifecycle from initial study startup through to regulatory submission, helping pharmaceutical sponsors and CROs standardize data and implement intelligent AI workflows.

Funding Details

Company Website: https://nphase.ai

Company: nPhase, Inc.
Raised: $30M
Round: Series D
Funding Date: November 2, 2026
Lead Investor: Viking Global Investors
Company Website: https://www.nphase.ai
Software Category: Clinical Research Technology
Source: https://www.hpcwire.com/aiwire/2026/11/02/nphase-secures-30m-series-d-for-clinical-data-management/